<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OALibJ</journal-id><journal-title-group><journal-title>Open Access Library Journal</journal-title></journal-title-group><issn pub-type="epub">2333-9705</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/oalib.1110816</article-id><article-id pub-id-type="publisher-id">OALibJ-128596</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biomedical&amp;Life Sciences</subject><subject> Business&amp;Economics</subject><subject> Chemistry&amp;Materials Science</subject><subject> Computer Science&amp;Communications</subject><subject> Earth&amp;Environmental Sciences</subject><subject> Engineering</subject><subject> Medicine&amp;Healthcare</subject><subject> Physics&amp;Mathematics</subject><subject> Social Sciences&amp;Humanities</subject></subj-group></article-categories><title-group><article-title>
 
 
  Epidemiological, Clinical and Therapeutic Aspects of Chronic Renal Failure at the Departmental University Hospital of Borgou and Alibori (CHUD/B-A) in Parakou (Benin)
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Coovi</surname><given-names>Nonwanou Ignace Tokpanoude</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Séraphin</surname><given-names>Ahoui</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Damien</surname><given-names>Barikissou Georgia</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>S.</surname><given-names>E. Elvire Djossou</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Sayo</surname><given-names>Djibo</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Benoit</surname><given-names>Agossoukpe</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Gottfid</surname><given-names>Agballa</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Vidékon</surname><given-names>Odjou</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ireti</surname><given-names>Nethania Elie Ataigba</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Badirou</surname><given-names>Aguemon</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>Institut de Formation en Soins Infirmiers et Obstétricaux (IFSIO), Faculté de Médecine (FMP), Parakou, Bénin</addr-line></aff><aff id="aff2"><addr-line>Unité de Santé Publique, Faculté des Sciences de la Santé, Université d’Abomey-Calavi, Abomey-Calavi, Bénin</addr-line></aff><aff id="aff1"><addr-line>Service de Néphrologie, Centre Hospitalier Universitaire et Départemental du Borgou Alibori (CHUD/B-A), Parakou, Bénin</addr-line></aff><pub-date pub-type="epub"><day>28</day><month>09</month><year>2023</year></pub-date><volume>10</volume><issue>10</issue><fpage>1</fpage><lpage>14</lpage><history><date date-type="received"><day>27,</day>	<month>September</month>	<year>2023</year></date><date date-type="rev-recd"><day>23,</day>	<month>October</month>	<year>2023</year>	</date><date date-type="accepted"><day>26,</day>	<month>October</month>	<year>2023</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Chronic kidney disease (CKD) remains underestimated in Africa, and particularly in Benin. Epidemiological data from different countries show a growing prevalence. This study aimed to investigate the epidemiological, clinical, and therapeutic aspects of chronic renal failure at the Departmental University Hospital of Borgou and l’Alibori (CHUD/B-A) in Parakou. This was a descriptive cross-sectional study conducted in the nephrology department of CHUD/B-A over 6 years from January 1, 2017, to December 31, 2022, involving chronic kidney disease patients with or without hemodialysis admitted to the nephrology department of CHUD/B-A. CKD was diagnosed according to the criteria of the International Classification of Chronic Kidney Diseases (KDIGO 2012). All patients meeting the inclusion criteria had been retained in the study. Data were analyzed using R 4.3.1 software. The mean with standard deviation was determined for quantitative variables. Qualitative variables were expressed as a proportion. The hospital prevalence of chronic renal failure was 55.2%. The prevalence of end-stage CKD was 72%. The mean age (SD) of patients was 50 years (&#177;14.9) [13 and 90 years]. Of these, 67% were male and 54.5% had no schooling or primary education. Hypertensives accounted for 58.6% of the sample, and 41.2% of patients were self-medicating. Most patients were seen in the context of an altered general condition. The main reason for consultation was asthenia. Biological disturbances were dominated by anemia (90.7%). The main drug groups used were antihypertensives (22.2%). Almost one case in four (24.5%) required hemodialysis. In conclusion, a reduction in unconventional therapeutic practices (self-medication and phytotherapy) is necessary to reduce its prevalence.
 
</p></abstract><kwd-group><kwd>Chronic Renal Failure</kwd><kwd> Chronic Kidney Disease</kwd><kwd> Epidemiology</kwd><kwd> Hemodialysis</kwd><kwd> Benin</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>The world is currently undergoing an epidemiological transition in which communicable diseases and epidemics, which once accounted for the lion’s share of the burden of disease and mortality, are gradually giving way to chronic and degenerative diseases, as well as accidents. Chronic kidney disease (CKD) is a non-communicable disease (NCD) that is attracting increasing scientific attention. Chronic kidney disease is the 11<sup>th</sup> leading cause of death worldwide [<xref ref-type="bibr" rid="scirp.128596-ref1">1</xref>] , and poses numerous management challenges for governments, particularly in low- and middle-income countries. One adult in ten suffers from chronic renal failure, and the mortality rate from kidney disease continues to rise every year [<xref ref-type="bibr" rid="scirp.128596-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.128596-ref3">3</xref>] . In the nephrology department of the National University Hospital Hubert Koutoukou Maga (CNHU-HKM) in Cotonou, CKD accounted for 91% of admissions in 2019 [<xref ref-type="bibr" rid="scirp.128596-ref4">4</xref>] . The commune of Parakou, which has a referral center receiving most of the nephrological pathologies in the northern part of the country, is also faced with the “epidemic” of chronic kidney disease. The aim of the present study was to investigate the epidemiological, clinical and therapeutic aspects of chronic renal failure at the Departmental University Hospital Center of Borgou and l’Alibori (CHUD/B-A) in Parakou.</p></sec><sec id="s2"><title>2. Materials and Methods</title><sec id="s2_1"><title>2.1. Type and Period of Study</title><p>This was a descriptive cross-sectional study conducted over a six-year period from January 1, 2017 to December 31, 2022, in the nephrology department of the Departmental University Hospital Center of Borgou and l’Alibori (CHUD-B/A) in Parakou, northeastern Benin.</p></sec><sec id="s2_2"><title>2.2. Inclusion Criteria</title><p>The study population consisted of patients diagnosed with chronic renal failure according to the classification criteria for chronic kidney disease [<xref ref-type="bibr" rid="scirp.128596-ref5">5</xref>] (KDIGO 2012). All patients received during the study period and meeting the diagnosis of CKD according to KDIGO 2012 regardless of stage were included in the study.</p></sec><sec id="s2_3"><title>2.3. Study Variables</title><p>・ Study variables were:</p><p>- Socio-demographic characteristics (age, gender, socio-professional group, professional status, marital status, place of residence, income, distance travelled).</p><p>- Lifestyle habits (herbal abuse, self-medication, alcohol abuse, tobacco abuse).</p><p>- Clinical data:</p><p>o Personal medical history and associated pathologies: hypertension, diabetes mellitus, stroke, urinary tract infections, heart failure, liver pathologies, bronchial asthma, human immunodeficiency virus (HIV) infection, prostate pathologies, polycystic kidney disease, cancers, gastric and duodenal ulcers, eclampsia).</p><p>o Clinical features (previous treatment, reason for consultation, mode of admission, general condition, vital signs, stage of chronic kidney disease, heart rate and blood pressure).</p><p>- Paraclinical characteristics (uremia, creatinemia, glomerular filtration rate (GFR), uric acid, natremia, kalemia, calcemia, total cholesterol, hemoglobin level and blood glucose).</p><p>- Therapeutic data (consultation time, number of molecules, hemodialysis treatment, duration of current treatment, time to first follow-up check-up).</p><p>・ Operational definitions of variables</p><p>- CKD was diagnosed according to the classification criteria for chronic kidney disease (KDIGO 2012). Stages 3, 4 and 5 were retained for a glomerular filtration rate (GFR) at entry of between: 30 and 59 mL/min/1.73m<sup>2</sup>; 15 and 29 mL/min/1.73m<sup>2</sup> and less than 15 mL/min/1.73m<sup>2</sup> respectively. The Chronic Kidney Disease―Epidemiology Collaboration (CKD-EPI) equation was used to calculate GFR [<xref ref-type="bibr" rid="scirp.128596-ref5">5</xref>] ;</p><p>- The distance travelled is the distance from the patient’s place of residence to the CHUD/D-A;</p><p>- Alcohol consumption was considered abusive (according to the WHO) if the subject consumed more than 21 glasses per week. Moreover, 1 glass of alcohol = 10 g of pure alcohol (according to the WHO) [<xref ref-type="bibr" rid="scirp.128596-ref6">6</xref>] ;</p><p>- Phytotherapy was abused by the subject, who regularly took a mixture of more than two elements per dose;</p><p>- Tobacco exposure was considered abusive in subjects who smoked more than once a day [<xref ref-type="bibr" rid="scirp.128596-ref6">6</xref>] ;</p><p>- Self-medication is defined as the habit of using one or more medicines without the intervention of a doctor or pharmacist, in order to treat oneself independently [<xref ref-type="bibr" rid="scirp.128596-ref7">7</xref>] ;</p><p>- The consultation delay is the time elapsed between the appearance of the first symptoms and the first contact with the health services;</p><p>- Initial check-up time is the time elapsed between diagnosis and the first check-up appointment;</p><p>- Treatment duration is the time spent in the department under treatment;</p><p>- Blood pressure was measured in seated patients after 15 minutes’ rest, using an automatic digital sphygmomanometer fitted with a cuff (belonging to the list of sphygmomanometers validated by the French Hypertension Society). It was taken on the bare right arm, placed on a table with the palm facing upwards. Three measurements were taken at 5-minute intervals; the average of the last two measurements was the blood pressure retained for each patient. Blood pressure was considered high if the post-measurement value was greater than or equal to 140/90 mmHg [<xref ref-type="bibr" rid="scirp.128596-ref8">8</xref>] ;</p><p>- Heart rate (HR) was considered normal for a number of heartbeats between 60 and 100 beats per minute. It was taken 15 minutes after the patient’s arrival, on the bare right arm, placed on a table, palm upwards, with the same automatic digital blood pressure meter fitted with a cuff used for blood pressure measurement;</p><p>- The following normal values were defined for paraclinical variables as follows: The following normal values were defined for paraclinical variables as follows:</p><p>o Hemoglobin in grams per deciliter (g/dL) between [11 - 16];</p><p>o Uremia in grams per liter (g/L) between [0.15 - 0.45];</p><p>o Plasma creatinine in mg/dL between [0.6 - 1.4];</p><p>o GFR greater than or equal to 90 mL/min/1.73m<sup>2</sup>;</p><p>o Uricemia in milligrams per liter (mg/L) between [40 - 60];</p><p>o Natremia in milliequivalents per liter (mEq/L) between [135 - 158];</p><p>o Kalemia (mEq/L) between [3.5 - 5.3];</p><p>o Calcemia (mEq/L) between [85 - 105];</p><p>o White blood cells per microliter (&#181;L) [3000 - 8000];</p><p>o Total cholesterol below 2 g/L;</p><p>o Fasting blood glucose (g/dL) between [0.70 - 1.26].</p></sec><sec id="s2_4"><title>2.4. Data Collection and Analysis</title><p>Data were collected using a medical record form, covering patients’ socio-demographic, clinical and therapeutic variables. Data were analyzed using R 4.3.1 software. The mean and standard deviation were determined for quantitative variables. Qualitative variables were expressed as a proportion.</p></sec></sec><sec id="s3"><title>3. Ethical Considerations</title><p>The survey protocol was validated by the public health unit of the Cotonou Faculty of Health Sciences. Collection authorizations were obtained from the aforementioned unit and from the head of the CHUD/B-A nephrology department. The anonymity and confidentiality of the data collected complied with the ethical principles applicable to medical research on human subjects contained in the Declaration of the World Medical Association of Helsinki.</p></sec><sec id="s4"><title>4. Results</title><p>From January 1, 2017 to December 31, 2022, a total of 621 cases were received in the nephrology department of CHUD/B-A, including 343 cases of chronic renal failure. The hospital prevalence of chronic renal failure was 55.2%. The prevalence of the different stages of CKD showed a predominance of the end-stage (72%) (<xref ref-type="fig" rid="fig1">Figure 1</xref> and <xref ref-type="fig" rid="fig2">Figure 2</xref>).</p><sec id="s4_1"><title>4.1. Socio-Demographic Characteristics</title><p>The mean age (SD) of patients was 50 years (&#177;14.9) [13 to 90 years]. Patients between 40 and 60 years of age were the most numerous. Nearly 67.1% of patients were male, giving a sex ratio (M/F) of 2.03. Most patients (36.4%) did not attend school. Civil servants, housewives and shopkeepers were the three predominant occupational groups, accounting for 14.3%, 23.6% and 15.2% of cases respectively. Two out of three patients (67.6%) were still working (<xref ref-type="table" rid="table1">Table 1</xref>).</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Distribution of patients by socio-demographic characteristics-CHUD/B-A, 2017-2022</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Effectif (n = 343)</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >Age range (year)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >[0 - 21[</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >2.0</td></tr><tr><td align="center" valign="middle" >[21 - 41[</td><td align="center" valign="middle" >93</td><td align="center" valign="middle" >27.2</td></tr><tr><td align="center" valign="middle" >[41 - 61[</td><td align="center" valign="middle" >161</td><td align="center" valign="middle" >46.9</td></tr><tr><td align="center" valign="middle" >[61 - 81[</td><td align="center" valign="middle" >75</td><td align="center" valign="middle" >21.9</td></tr><tr><td align="center" valign="middle" >≥81</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >2.0</td></tr><tr><td align="center" valign="middle" >Gender</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Male</td><td align="center" valign="middle" >230</td><td align="center" valign="middle" >67.1</td></tr><tr><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >113</td><td align="center" valign="middle" >32.9</td></tr><tr><td align="center" valign="middle" >Residence</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Urban</td><td align="center" valign="middle" >229</td><td align="center" valign="middle" >66.8</td></tr><tr><td align="center" valign="middle" >Rural</td><td align="center" valign="middle" >114</td><td align="center" valign="middle" >33.2</td></tr><tr><td align="center" valign="middle"  colspan="3"  >Distance travelled (Km)</td></tr><tr><td align="center" valign="middle" >≤50</td><td align="center" valign="middle" >211</td><td align="center" valign="middle" >61.5</td></tr><tr><td align="center" valign="middle" >&gt;50</td><td align="center" valign="middle" >132</td><td align="center" valign="middle" >38.5</td></tr><tr><td align="center" valign="middle" >Study level</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >No schooling</td><td align="center" valign="middle" >125</td><td align="center" valign="middle" >36.4</td></tr><tr><td align="center" valign="middle" >Primary level</td><td align="center" valign="middle" >62</td><td align="center" valign="middle" >18.1</td></tr><tr><td align="center" valign="middle" >Secondary level</td><td align="center" valign="middle" >79</td><td align="center" valign="middle" >23.0</td></tr><tr><td align="center" valign="middle" >Higher education</td><td align="center" valign="middle" >77</td><td align="center" valign="middle" >22.5</td></tr><tr><td align="center" valign="middle" >Marital status</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Unmarried</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >9.3</td></tr><tr><td align="center" valign="middle" >Married</td><td align="center" valign="middle" >311</td><td align="center" valign="middle" >90.7</td></tr><tr><td align="center" valign="middle" >Professional status</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Still working</td><td align="center" valign="middle" >232</td><td align="center" valign="middle" >67.6</td></tr><tr><td align="center" valign="middle" >Unemployed</td><td align="center" valign="middle" >61</td><td align="center" valign="middle" >17.8</td></tr><tr><td align="center" valign="middle" >Retired patient</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >14.6</td></tr><tr><td align="center" valign="middle" >Socio-professional group</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Workers and craftsmen</td><td align="center" valign="middle" >49</td><td align="center" valign="middle" >14.4</td></tr><tr><td align="center" valign="middle" >Civil servants</td><td align="center" valign="middle" >81</td><td align="center" valign="middle" >23.6</td></tr><tr><td align="center" valign="middle" >Housewives</td><td align="center" valign="middle" >52</td><td align="center" valign="middle" >15.3</td></tr><tr><td align="center" valign="middle" >Traders. retailers</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >14.6</td></tr><tr><td align="center" valign="middle" >Fishermen farmers and breeders</td><td align="center" valign="middle" >49</td><td align="center" valign="middle" >14.3</td></tr><tr><td align="center" valign="middle" >Drivers. transporters</td><td align="center" valign="middle" >37</td><td align="center" valign="middle" >10.8</td></tr><tr><td align="center" valign="middle" >Other professions</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >3.8</td></tr></tbody></table></table-wrap></sec><sec id="s4_2"><title>4.2. Associated Pathologies and Lifestyle</title><p>Arterial hypertension (AH) and diabetes mellitus were the associated pathologies most frequently found in patients, accounting for 59.1% and 18.1% of cases respectively (<xref ref-type="fig" rid="fig3">Figure 3</xref>). The lifestyle habit most frequently incriminated was self-medication (41.2%) (<xref ref-type="fig" rid="fig3">Figure 3</xref> and <xref ref-type="fig" rid="fig4">Figure 4</xref>).</p></sec><sec id="s4_3"><title>4.3. Clinical Characteristics</title><p>Most patients (47.2%) had consulted their doctor within three months, most often in a context of deteriorating general condition. The vast majority (85.4%) had received treatment prior to admission. The main reasons for consultation were asthenia, headaches and dyspnea, as well as edema. In 44% of cases, renal function was already impaired on admission. According to the mode of admission to the department, 66% of patients had been referred by healthcare professionals, the majority of whom (70%) were general practitioners. Tachycardia was observed in 32.7% of patients, and high blood pressure in 72% (<xref ref-type="table" rid="table2">Table 2</xref>).</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Distribution of patients according to their clinical characteristics, CHUD/B-A, 2017-2022</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Frequency (n = 343)</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >Consultation lead time (in days)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≤7</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >1.7</td></tr><tr><td align="center" valign="middle" >[8 - 91[</td><td align="center" valign="middle" >162</td><td align="center" valign="middle" >47.3</td></tr><tr><td align="center" valign="middle" >[91 - 181[</td><td align="center" valign="middle" >67</td><td align="center" valign="middle" >19.5</td></tr><tr><td align="center" valign="middle" >≥181</td><td align="center" valign="middle" >108</td><td align="center" valign="middle" >31.5</td></tr><tr><td align="center" valign="middle" >Consultation reasons</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Impaired renal function</td><td align="center" valign="middle" >215</td><td align="center" valign="middle" >44.1</td></tr><tr><td align="center" valign="middle" >Asthenia/headache/dyspnea</td><td align="center" valign="middle" >114</td><td align="center" valign="middle" >15.5</td></tr><tr><td align="center" valign="middle" >Edema</td><td align="center" valign="middle" >39</td><td align="center" valign="middle" >9.7</td></tr><tr><td align="center" valign="middle" >Digestive signs (anorexia/nausea/vertigo)</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >4.4</td></tr><tr><td align="center" valign="middle" >Urinary symptoms</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >3.1</td></tr><tr><td align="center" valign="middle" >Altered state of consciousness</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >1.4</td></tr><tr><td align="center" valign="middle" >Weight loss</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >1.6</td></tr><tr><td align="center" valign="middle" >Past treatment</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >14.6</td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >293</td><td align="center" valign="middle" >85.4</td></tr><tr><td align="center" valign="middle" >Patient’s general condition</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Good</td><td align="center" valign="middle" >69</td><td align="center" valign="middle" >20.1</td></tr><tr><td align="center" valign="middle" >Altered</td><td align="center" valign="middle" >275</td><td align="center" valign="middle" >79.9</td></tr><tr><td align="center" valign="middle" >Method of admission</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Direct</td><td align="center" valign="middle" >117</td><td align="center" valign="middle" >34.1</td></tr><tr><td align="center" valign="middle" >Referred</td><td align="center" valign="middle" >226</td><td align="center" valign="middle" >65.9</td></tr><tr><td align="center" valign="middle" >Heart rate</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Normal</td><td align="center" valign="middle" >231</td><td align="center" valign="middle" >67.4</td></tr><tr><td align="center" valign="middle" >Tachycardia</td><td align="center" valign="middle" >112</td><td align="center" valign="middle" >32.7</td></tr><tr><td align="center" valign="middle" >Blood pressure</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Normal</td><td align="center" valign="middle" >96</td><td align="center" valign="middle" >28.0</td></tr><tr><td align="center" valign="middle" >High</td><td align="center" valign="middle" >247</td><td align="center" valign="middle" >72.0</td></tr></tbody></table></table-wrap></sec><sec id="s4_4"><title>4.4. Patient Characteristics Related to Their Biological Tests</title><p>Mean GFR (SD) was 11.9 mL/min/1.73m<sup>2</sup> (&#177;13.3). Main disturbances revealed by paraclinical examinations were: anemia (90.7%), hyperuricemia (86.3%), hyperuricemia (77.6%), hypocalcemia (40.2%), hyponatremia (31.2%), hypercholesterolemia (29.7%) hyperleukocytosis (29.7%), hyperkalemia (19.5%) and hyperglycemia (13.4%) (<xref ref-type="table" rid="table3">Table 3</xref>).</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Distribution of patients according to the characteristics of their paraclinical examinations, CHUD/B-A 2017-2022</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Frequency (n = 343)</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >Uremia</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Normal</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >13.7</td></tr><tr><td align="center" valign="middle" >High</td><td align="center" valign="middle" >296</td><td align="center" valign="middle" >86.3</td></tr><tr><td align="center" valign="middle" >Uricemia</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Low</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >9.3</td></tr><tr><td align="center" valign="middle" >Normal</td><td align="center" valign="middle" >45</td><td align="center" valign="middle" >13.1</td></tr><tr><td align="center" valign="middle" >High</td><td align="center" valign="middle" >266</td><td align="center" valign="middle" >77.6</td></tr><tr><td align="center" valign="middle" >Hemoglobin level</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Low</td><td align="center" valign="middle" >311</td><td align="center" valign="middle" >90.7</td></tr><tr><td align="center" valign="middle" >Normal</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >9.3</td></tr><tr><td align="center" valign="middle" >Blood glucose</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Low</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >7.6</td></tr><tr><td align="center" valign="middle" >Normal</td><td align="center" valign="middle" >271</td><td align="center" valign="middle" >79.0</td></tr><tr><td align="center" valign="middle" >High</td><td align="center" valign="middle" >46</td><td align="center" valign="middle" >13.4</td></tr><tr><td align="center" valign="middle" >Natremia</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Low</td><td align="center" valign="middle" >107</td><td align="center" valign="middle" >31.2</td></tr><tr><td align="center" valign="middle" >Normal</td><td align="center" valign="middle" >220</td><td align="center" valign="middle" >64.1</td></tr><tr><td align="center" valign="middle" >High</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >4.7</td></tr><tr><td align="center" valign="middle" >Kalemia</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Low</td><td align="center" valign="middle" >44</td><td align="center" valign="middle" >12.8</td></tr><tr><td align="center" valign="middle" >Normal</td><td align="center" valign="middle" >232</td><td align="center" valign="middle" >67.6</td></tr><tr><td align="center" valign="middle" >High</td><td align="center" valign="middle" >67</td><td align="center" valign="middle" >19.5</td></tr><tr><td align="center" valign="middle" >Calcemia</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Low</td><td align="center" valign="middle" >138</td><td align="center" valign="middle" >40.2</td></tr><tr><td align="center" valign="middle" >Normal</td><td align="center" valign="middle" >191</td><td align="center" valign="middle" >55.7</td></tr><tr><td align="center" valign="middle" >High</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >4.1</td></tr><tr><td align="center" valign="middle" >White blood cell count</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Normal</td><td align="center" valign="middle" >241</td><td align="center" valign="middle" >70,3</td></tr><tr><td align="center" valign="middle" >High</td><td align="center" valign="middle" >102</td><td align="center" valign="middle" >29.7</td></tr><tr><td align="center" valign="middle" >Total cholesterol</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Normal</td><td align="center" valign="middle" >241</td><td align="center" valign="middle" >70.3</td></tr><tr><td align="center" valign="middle" >High</td><td align="center" valign="middle" >102</td><td align="center" valign="middle" >29.7</td></tr></tbody></table></table-wrap></sec><sec id="s4_5"><title>4.5. Patient Therapeutic Characteristics</title><p>All patients consulted during the study period had received advice on dietary and nutritional measures, as well as drug prescriptions. The majority of patients were seen in the terminal stage of the disease (stage 5). Most of them (82.2%) had spent less than a year on treatment in the department. The main drug groups used were antihypertensives (22.2%), alkalinizes and calcium (18.7%) and antianemics (17.8%) (<xref ref-type="table" rid="table4">Table 4</xref>).</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Distribution of patients according to therapeutic management―CHUD/B-A, 2017-2022</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Frequency (n = 343)</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >Therapeutic decisions</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Outpatient treatment</td><td align="center" valign="middle" >237</td><td align="center" valign="middle" >64.4</td></tr><tr><td align="center" valign="middle" >Hospitalization</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >7.9</td></tr><tr><td align="center" valign="middle" >Hemodialysis</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >27.2</td></tr><tr><td align="center" valign="middle" >References</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.5</td></tr><tr><td align="center" valign="middle" >Drug group</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Antihypertensives</td><td align="center" valign="middle" >291</td><td align="center" valign="middle" >22.2</td></tr><tr><td align="center" valign="middle" >Alkalizing agents/calcium/vitamin D/magnesium</td><td align="center" valign="middle" >245</td><td align="center" valign="middle" >18.7</td></tr><tr><td align="center" valign="middle" >Antianemics</td><td align="center" valign="middle" >234</td><td align="center" valign="middle" >17.8</td></tr><tr><td align="center" valign="middle" >Diuretics</td><td align="center" valign="middle" >150</td><td align="center" valign="middle" >11.4</td></tr><tr><td align="center" valign="middle" >Vitamins and micronutrients</td><td align="center" valign="middle" >147</td><td align="center" valign="middle" >11.2</td></tr><tr><td align="center" valign="middle" >Hypouricemic</td><td align="center" valign="middle" >108</td><td align="center" valign="middle" >8.2</td></tr><tr><td align="center" valign="middle" >Antidiabetics</td><td align="center" valign="middle" >57</td><td align="center" valign="middle" >4.3</td></tr><tr><td align="center" valign="middle" >Antibiotics</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >2.0</td></tr><tr><td align="center" valign="middle" >Potassium chelators</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >1.8</td></tr><tr><td align="center" valign="middle" >Anxiolytics. antiemetics. statins</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >1.4</td></tr><tr><td align="center" valign="middle" >Hemodialysis</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >259</td><td align="center" valign="middle" >75.5</td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >84</td><td align="center" valign="middle" >24.5</td></tr><tr><td align="center" valign="middle" >Duration of treatment (years)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;1</td><td align="center" valign="middle" >282</td><td align="center" valign="middle" >82.2</td></tr><tr><td align="center" valign="middle" >≥1</td><td align="center" valign="middle" >61</td><td align="center" valign="middle" >17.8</td></tr><tr><td align="center" valign="middle"  colspan="3"  >Time to first follow-up (days)</td></tr><tr><td align="center" valign="middle" >≤30</td><td align="center" valign="middle" >217</td><td align="center" valign="middle" >63.3</td></tr><tr><td align="center" valign="middle" >≥31</td><td align="center" valign="middle" >126</td><td align="center" valign="middle" >36.3</td></tr></tbody></table></table-wrap></sec></sec><sec id="s5"><title>5. Discussion</title><sec id="s5_1"><title>5.1. Hospital Prevalence</title><p>Chronic renal failure is a frequent condition in the CHUD/B-A nephrology department. Its hospital prevalence was 55.2%. This prevalence is close to that of Eyeni Sinomono et al. [<xref ref-type="bibr" rid="scirp.128596-ref9">9</xref>] who reported that CKD accounted for 50.7% of admissions to the nephrology department of Brazzaville University Hospital. This is lower than that reported by Vigan et al. [<xref ref-type="bibr" rid="scirp.128596-ref4">4</xref>] in whom CKD accounted for 91% of admissions in the nephrology department of the CNHU-HKM in Cotonou, Benin.</p><p>However, our prevalence is higher than that of Gbaguidi et al. [<xref ref-type="bibr" rid="scirp.128596-ref10">10</xref>] , who reported a prevalence of 16.1%. This difference is due to the fact that this study was carried out in a general population, in a rural setting, unlike ours, which was carried out in a hospital setting, in a specialized department.</p></sec><sec id="s5_2"><title>5.2. Socio-Demographic Characteristics of Patients</title><p>Age and gender: In our study, the mean age of patients was 50 &#177; 14.9 years. The majority were 60 years old. Our average age is close to those of 47 and 52 years reported in Benin [<xref ref-type="bibr" rid="scirp.128596-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.128596-ref10">10</xref>] ; 51.4 years in DRC [<xref ref-type="bibr" rid="scirp.128596-ref11">11</xref>] ; 51.2 years in Congo [<xref ref-type="bibr" rid="scirp.128596-ref9">9</xref>] . On the other hand, it is lower than the average of 72 years reported in France [<xref ref-type="bibr" rid="scirp.128596-ref12">12</xref>] .</p><p>Male patients were the most affected, accounting for 67.1% of cases. The same male predominance was reported by Tia, et al. Ahoui et al. and Vigan et al. [<xref ref-type="bibr" rid="scirp.128596-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.128596-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.128596-ref14">14</xref>] .</p><sec id="s5_2_1"><title>5.2.1. Profession</title><p>Housewives, shopkeepers and farmers were the predominant professions, in line with the socio-professional groups reported by Ahoui and Vigan et al. [<xref ref-type="bibr" rid="scirp.128596-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.128596-ref14">14</xref>] . Chronic kidney disease affects active people. Like all non-communicable diseases, it is responsible for a drop in the productivity of affected patients, which sustains poverty. Its progression to end-stage renal disease, possibly followed by dialysis, represents a major health burden for patients’ families.</p></sec><sec id="s5_2_2"><title>5.2.2. Level of Education</title><p>Patients with no schooling (36.4%) were the most likely to have consulted a doctor. This proportion is close to the 27.9% reported by Ahoui et al. [<xref ref-type="bibr" rid="scirp.128596-ref14">14</xref>] . The same finding (72.1%) was made by Gbaguidi et al. [<xref ref-type="bibr" rid="scirp.128596-ref10">10</xref>] , but in a higher proportion. This result raises the issue of the content of the information to be used to raise awareness among the most vulnerable groups.</p></sec><sec id="s5_2_3"><title>5.2.3. Medical History and Lifestyle</title><p>Patients with a history of hypertension (59.1%) or diabetes mellitus (18.1%) were the most numerous. Ramilitiana et al. [<xref ref-type="bibr" rid="scirp.128596-ref15">15</xref>] had reported that in subjects with chronic renal failure, hypertension and diabetes were found in 41.3% and 17.2% of cases respectively. Amekoud et al. [<xref ref-type="bibr" rid="scirp.128596-ref16">16</xref>] also reported that hypertension was known in 63.5% of patients, and was the main antecedent. Stengel et al. [<xref ref-type="bibr" rid="scirp.128596-ref12">12</xref>] reported that almost one in two cases of end-stage renal failure was secondary to hypertension or diabetes, mainly type 2, non-insulin-dependent diabetes.</p><p>Among the lifestyle habits most frequently found in our study were herbal medicine and alcohol and tobacco consumption. Ahoui et al. [<xref ref-type="bibr" rid="scirp.128596-ref14">14</xref>] had reported the same lifestyle habits.</p></sec><sec id="s5_2_4"><title>5.2.4. Clinical Characteristics</title><p>Patients were seen mainly for impaired renal function, asthenia, edema, dyspnea and anorexia. Biologically observed renal function impairment (44.06%) is a reason for consultation occurred only in a referral context or is an incidental finding during a consultation for another condition. The same finding was reported by Ahoui et al. [<xref ref-type="bibr" rid="scirp.128596-ref14">14</xref>] , for whom asthenia was the most constant general sign.</p></sec><sec id="s5_2_5"><title>5.2.5. Therapeutic Characteristics</title><p>The majority of patients were admitted with stage 5 disease (72%). This proportion is close to that reported by Vigan et al. [<xref ref-type="bibr" rid="scirp.128596-ref4">4</xref>] who reported that stage 5 chronic renal failure was observed in 78% of patients. The same observation was made in Togo and Nigeria for 44.8% and 42% of samples respectively [<xref ref-type="bibr" rid="scirp.128596-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.128596-ref18">18</xref>] . Screening patients for non-communicable disease risk factors at every contact with a physician would help to identify CKD patients as early as possible, and thus improve management. Most patients (82.22%) had spent less than a year in the department. The same observation was made by Thanh et al. [<xref ref-type="bibr" rid="scirp.128596-ref19">19</xref>] who reported that adherence to CKD treatment in patients aged 18 or over was such that around 30% of patients would not be persistent one year after starting treatment or compliant within one year of initiation.</p></sec></sec></sec><sec id="s6"><title>6. Conclusion</title><p>The hospital prevalence of renal failure was high in the CHUD/B-A nephrology department. It was much more prevalent in active people under 60. Self-medication and alcohol abuse were the lifestyles most commonly found in our patients. Arterial hypertension and diabetes were the comorbidities present in our patients. The patients, for the most part referred, had arrived at the terminal stage in an altered general state. Proper management of non-communicable diseases such as hypertension and diabetes could help reduce disease prevalence. Chronic renal failure remains a public health concern in our region, due to its complications and costly management. A reduction in unconventional therapeutic practices (self-medication and phytotherapy) is necessary to reduce its prevalence.</p></sec><sec id="s7"><title>Acknowledgements</title><p>Our thanks go to the staff of CHUD/B-A and colleagues from the Public Health Unit of the Faculty of Health Sciences (FSS).</p><p>Authors’ contributions: All authors have contributed to the correction of the document.</p></sec><sec id="s8"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec id="s9"><title>Cite this paper</title><p>Tokpanoude, C.N.I., Ahoui, S., Georgia, D.B., Djossou, S.E.E., Djibo, S., Agossoukpe, B., Agballa, G., Odjou, V., Ataigba, I.N.E. and Aguemon, B. (2023) Epidemiological, Clinical and The- rapeutic Aspects of Chronic Renal Failure at the Departmental University Hospital of Borgou and Alibori (CHUD/B-A) in Parakou (Benin). Open Access Library Journal, 10: e10816 https://doi.org/10.4236/oalib.1110816</p></sec></body><back><ref-list><title>References</title><ref id="scirp.128596-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">WHO (2022) Maladies Non Transmissibles. 
https://www.who.int/fr/news-room/fact-sheets/detail/noncommunicable-diseases</mixed-citation></ref><ref id="scirp.128596-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization, Public Health Agency of Canada (2005) Preventing Chronic Diseases: A Vital Investment. World Health Organization, Public Health Agency of Canada, 182 p.</mixed-citation></ref><ref id="scirp.128596-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Maurizi-Balzan, J. and Zaoui, P. (2003) Insuffisance rénale chronique.  
https://fr.scribd.com/document/142644791/Insuffisance-Renale-Chronique</mixed-citation></ref><ref id="scirp.128596-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Vigan, J., Agboton, B., Ahoui, S., Ali Rouffa, H. and Djrolo, F. (2018) Profil épidemiologique de la maladie rénale chronique dans le service de néphrologie du CNHU-HKM de Cotonou. Journal de la Société de Biologie Clinique du Bénin, 29, 5-11.</mixed-citation></ref><ref id="scirp.128596-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">The Kidney Disease Improving Global Outcomes (KDIGO) Working Group (2012) Definition and Classification of Acute Kidney Injury.</mixed-citation></ref><ref id="scirp.128596-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Halimi, S. (2007) Médecine des maladies Métaboliques: Glycémie postprandiale. Médecine des Maladies Métaboliques, 1, 21. 
https://doi.org/10.1016/S1957-2557(07)88653-6</mixed-citation></ref><ref id="scirp.128596-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Fournier, J.-P. and Brutus, L. (2018) Automédication. EM Consulte.</mixed-citation></ref><ref id="scirp.128596-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Williams, B. and Mancia, G. (2018) Ten Commandments of the 2018 ESC/ESH HTN Guidelines on Hypertension in Adults. European Heart Journal, 39, 3007-3008.  
https://doi.org/10.1093/eurheartj/ehy439</mixed-citation></ref><ref id="scirp.128596-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Eyeni Sinomono, D.T., Gassongo Koumou, G.C. and Loumingou, R. (2017) Profil épidémiologique de l’insuffisance rénale chronique au CHU de Brazzaville en 2016. Néphrologie &amp; Thérapeutique, 13, 396.  
https://doi.org/10.1016/j.nephro.2017.08.302</mixed-citation></ref><ref id="scirp.128596-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Gwladys, G., Houehanou, C.Y., Amidou, S.A.,Vigan, J., Houinato, D.S. and Lacroix, P. (2020) Insuffisance rénale chronique: prévalence et facteurs associés dans une population rurale au Bénin. Néphrologie &amp; Thérapeutique, 16, 252. 
https://doi.org/10.1016/j.nephro.2020.07.016</mixed-citation></ref><ref id="scirp.128596-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Ngoie, S.M., Mulenga, P., Mukuku, O., Kakisingi, C.N., Sangwa, C.M., Nawej, P.T., et al. (2017) Maladie rénale chronique: facteurs associés, étiologies, caractéristiques clinique et biologique à Lubumbashi en République Démocratique du Congo. Pan African Medical Journal, 28, 41. https://doi.org/10.11604/pamj.2017.28.41.9810</mixed-citation></ref><ref id="scirp.128596-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Stengel, B., Combe, C., Jacquelinet, C., Brianon, S., Fouque, D., Laville, M., et al. (2016) The French Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) Cohort Study: To Better Understand chRonic Kidney Disease. Néphrologie &amp; Thérapeutique, 12, S49-56.</mixed-citation></ref><ref id="scirp.128596-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Tia, M.W., Nda, J.K., Kouame, G.R., Kobenan, R., Daingui, D. and Ouattara, B. (2022) Insuffisance rénale chronique: Aspects épidémiologique, diagnostique, thérapeutique et évolutif au CHU de Bouaké de 2016 à 2020. Revue Africaine de Médecine Interne, 9, 60-66.</mixed-citation></ref><ref id="scirp.128596-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Ahoui, S., Dovonou, C.A., Vigan, J., Agboton, B.L., Alassani, C.A., Doritchamou, E., et al. (2021) Fréquence et facteurs associés à l’insuffisance rénale chronique dans le service de médecine interne du centre hospitalier universitaire départemental du Borgou. Revue Africaine de Médecine Interne, 8, 8-16.</mixed-citation></ref><ref id="scirp.128596-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Ramilitiana, B., Ranivoharisoa, E.M., Dodo, M., Razafimandimby, E. and Randri- amarotia, W.F. (2016) Une étude rétrospective sur l’incidence de l’insuffisance rénale chronique dans le service de Médecine Interne et Néphrologie du Centre Hospitalier Universitaire d’Antananarivo. Pan African Medical Journal, 23, 141.  
https://doi.org/10.11604/pamj.2016.23.141.8874</mixed-citation></ref><ref id="scirp.128596-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Amekoudi, E.Y., Sabi, K.A., Noto-Kadou-Kaza, B. and Combe, C. (2016) épidé- miologie de la maladie rénale chronique en consultation de néphrologie au CHU Sylvanus-Olympio du Togo. Néphrologie &amp; Thérapeutique, 12, 400. 
https://doi.org/10.1016/j.nephro.2016.07.113</mixed-citation></ref><ref id="scirp.128596-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Tsevi, Y.M., Dolaama, B., Tona, K.G., Tevi, A.A., Affanou, E.C., Amede, A.D., et al. (2021) Insuffisance rénale chronique et hémodialyse à Lomé: l′hémodialysé et son entourage sont-ils bien informés? Pan African Medical Journal, 39, 85. 
https://doi.org/10.11604/pamj.2021.39.85.26685</mixed-citation></ref><ref id="scirp.128596-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Ulasi, I.I., Ijoma, C.K., Onodugo, O.D., Arodiwe, E.B., Ifebunandu, N.A. and Okoye, J.U. (2013) Towards Prevention of Chronic Kidney Disease in Nigeria: A Community-Based Study in Southeast Nigeria. Kidney International Supplements, 3, 195-201. https://doi.org/10.1038/kisup.2013.13</mixed-citation></ref><ref id="scirp.128596-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Truong, V.T. (2016) Adhésion au traitement de la maladie rénale chronique chez les québécois agés de 18 ans ou plus.</mixed-citation></ref></ref-list></back></article>